DreamCIS, Inc. (KOSDAQ:223250)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,010.00
-10.00 (-0.20%)
At close: Apr 24, 2026
Market Cap123.13B +89.5%
Revenue (ttm)66.63B +13.6%
Net Income7.13B +35.0%
EPS298.00 +34.8%
Shares Out24.58M
PE Ratio16.81
Forward PE11.41
Dividendn/a
Ex-Dividend Daten/a
Volume60,332
Average Volume67,431
Open5,020.00
Previous Close5,020.00
Day's Range4,850.00 - 5,080.00
52-Week Range2,805.00 - 8,070.00
Beta0.49
RSI50.55
Earnings DateMay 11, 2026

About DreamCIS

DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd. [Read more]

Industry Commercial Physical and Biological Research
Founded 2000
Employees 391
Stock Exchange KOSDAQ
Ticker Symbol 223250
Full Company Profile

Financial Performance

In 2025, DreamCIS's revenue was 66.63 billion, an increase of 13.60% compared to the previous year's 58.65 billion. Earnings were 7.13 billion, an increase of 34.97%.

Financial Statements